Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuekai Zhu

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Oncoscience|June 23, 2015
Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cellsXuekai Zhu, Gabriele Niedermann
Briefings in Functional Genomics|July 9, 2018
Next-generation sequencing technologies accelerate advances in T-cell therapy for cancerQinan Yin, Jiaxing Tang, Xuekai Zhu
Oncotarget|November 27, 2014
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57Xuekai Zhu, Shruthi Prasad, Simone Gaedicke, et al.
Frontiers of Computer Science|December 19, 2022
FragDPI: a novel drug-protein interaction prediction model based on fragment understanding and unified codingZhihui Yang, Juan Liu, Xuekai Zhu, et al.
Computational Biology and Chemistry|April 9, 2024
Advancing Drug-Target Interaction prediction with BERT and subsequence embeddingZhihui Yang, Juan Liu, Feng Yang, et al.
Human Gene Therapy|May 1, 2018
Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T CellsBian Hu, Yan Zou, Linlin Zhang, et al.
Theranostics|May 11, 2016
Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific AntibodiesHua Jing, Claudia Weidensteiner, Wilfried Reichardt, et al.
Frontiers in Pharmacology|March 29, 2021
BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b ReceptorJiaxing Tang, Yan Zou, Long Li, et al.
Cancer Letters|October 23, 2021
IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumorsYan Zou, Bo Liu, Long Li, et al.
Protein Engineering, Design & Selection : PEDS|March 30, 2013
Generation of single-domain antibody multimers with three different self-associating peptidesLifei Wang, Xiaoli Liu, Xuekai Zhu, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Oncoscience|June 23, 2015
Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cellsXuekai Zhu, Gabriele Niedermann
Briefings in Functional Genomics|July 9, 2018
Next-generation sequencing technologies accelerate advances in T-cell therapy for cancerQinan Yin, Jiaxing Tang, Xuekai Zhu
Oncotarget|November 27, 2014
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57Xuekai Zhu, Shruthi Prasad, Simone Gaedicke, et al.
Frontiers of Computer Science|December 19, 2022
FragDPI: a novel drug-protein interaction prediction model based on fragment understanding and unified codingZhihui Yang, Juan Liu, Xuekai Zhu, et al.
Computational Biology and Chemistry|April 9, 2024
Advancing Drug-Target Interaction prediction with BERT and subsequence embeddingZhihui Yang, Juan Liu, Feng Yang, et al.
Human Gene Therapy|May 1, 2018
Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T CellsBian Hu, Yan Zou, Linlin Zhang, et al.
Theranostics|May 11, 2016
Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific AntibodiesHua Jing, Claudia Weidensteiner, Wilfried Reichardt, et al.
Frontiers in Pharmacology|March 29, 2021
BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b ReceptorJiaxing Tang, Yan Zou, Long Li, et al.
Cancer Letters|October 23, 2021
IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumorsYan Zou, Bo Liu, Long Li, et al.
Protein Engineering, Design & Selection : PEDS|March 30, 2013
Generation of single-domain antibody multimers with three different self-associating peptidesLifei Wang, Xiaoli Liu, Xuekai Zhu, et al.
Pageof 3